scholarly journals Oligomers of the Arginine-rich Motif of the HIV-1 TAT Protein Are Capable of Transferring Plasmid DNA into Cells

2003 ◽  
Vol 278 (13) ◽  
pp. 11411-11418 ◽  
Author(s):  
Carsten Rudolph ◽  
Christian Plank ◽  
James Lausier ◽  
Ulrike Schillinger ◽  
Rainer H. Müller ◽  
...  
2003 ◽  
Vol 278 (43) ◽  
pp. 42625-42636 ◽  
Author(s):  
Irina A. Ignatovich ◽  
Ella B. Dizhe ◽  
Anna V. Pavlotskaya ◽  
Boris N. Akifiev ◽  
Sergey V. Burov ◽  
...  

2014 ◽  
Vol 140 ◽  
pp. e141-e142
Author(s):  
Jay P. McLaughlin ◽  
M.L. Ganno ◽  
S.O. Eans ◽  
Jason J. Paris ◽  
H.D. Singh

1993 ◽  
Vol 268 (7) ◽  
pp. 5279-5284
Author(s):  
B.S. Weeks ◽  
K. Desai ◽  
P.M. Loewenstein ◽  
M.E. Klotman ◽  
P.E. Klotman ◽  
...  

FEBS Letters ◽  
2000 ◽  
Vol 485 (2-3) ◽  
pp. 163-167 ◽  
Author(s):  
Hyeok Yil Kwon ◽  
Won Sik Eum ◽  
Hyun Woo Jang ◽  
Jung Hoon Kang ◽  
Jiyoon Ryu ◽  
...  

2000 ◽  
Vol 74 (4) ◽  
pp. 1632-1640 ◽  
Author(s):  
Siew Pheng Lim ◽  
Alfredo Garzino-Demo

ABSTRACT It has been shown that the human immunodeficiency virus type 1 (HIV-1) Tat protein can specifically enhance expression and release of monocyte chemoattractant protein 1 (MCP-1) from human astrocytes. In this study, we show evidence that Tat-induced MCP-1 expression is mediated at the transcriptional level. Transient transfection of an expression construct encoding the full-length Tat into the human glioblastoma-astrocytoma cell line U-87 MG enhances reporter gene activity from cotransfected deletion constructs of the MCP-1 promoter. HIV-1 Tat exerts its effect through a minimal construct containing 213 nucleotides upstream of the translational start site. Site-directed mutagenesis studies indicate that an SP1 site (located between nucleotides −123 and −115) is critical for both constitutive and Tat-enhanced expression of the human MCP-1 promoter, as mutation of this SP1 site significantly diminished reporter gene expression in both instances. Gel retardation experiments further demonstrate that Tat strongly enhances the binding of SP1 protein to its DNA element on the MCP-1 promoter. Moreover, we also observe an increase in the binding activities of transcriptional factors AP1 and NF-κB to the MCP-1 promoter following Tat treatment. Mutagenesis studies show that an upstream AP1 site and an adjacent NF-κB site (located at −128 to −122 and −150 to −137, respectively) play a role in Tat-mediated transactivation. In contrast, a further upstream AP1 site (−156 to −150) does not appear to be crucial for promoter activity. We postulate that a Tat-mediated increase in SP1 binding activities augments the binding of AP1 and NF-κB, leading to synergistic activation of the MCP-1 promoter.


2001 ◽  
Vol 75 (16) ◽  
pp. 7621-7628 ◽  
Author(s):  
Julianna Lisziewicz ◽  
Dmitry I. Gabrilovich ◽  
Georg Varga ◽  
Jianqing Xu ◽  
Philip D. Greenberg ◽  
...  

ABSTRACT A novel technology combining replication- and integration-defective human immunodeficiency virus type 1 (HIV-1) vectors with genetically modified dendritic cells was developed in order to induce T-cell immunity. We introduced the vector into dendritic cells as a plasmid DNA using polyethylenimine as the gene delivery system, thereby circumventing the problem of obtaining viral vector expression in the absence of integration. Genetically modified dendritic cells (GMDC) presented viral epitopes efficiently, secreted interleukin 12, and primed both CD4+ and CD8+ HIV-specific T cells capable of producing gamma interferon and exerting potent HIV-1-specific cytotoxicity in vitro. In nonhuman primates, subcutaneously injected GMDC migrated into the draining lymph node at an unprecedentedly high rate and expressed the plasmid DNA. The animals presented a vigorous HIV-specific effector cytotoxic-T-lymphocyte (CTL) response as early as 3 weeks after a single immunization, which later developed into a memory CTL response. Interestingly, antibodies did not accompany these CTL responses, indicating that GMDC can induce a pure Th1 type of immune response. Successful induction of a broad and long-lasting HIV-specific cellular immunity is expected to control virus replication in infected individuals.


Science ◽  
1990 ◽  
Vol 249 (4974) ◽  
pp. 1281-1285 ◽  
Author(s):  
K. Weeks ◽  
C Ampe ◽  
S. Schultz ◽  
T. Steitz ◽  
D. Crothers
Keyword(s):  
Tar Rna ◽  

Sign in / Sign up

Export Citation Format

Share Document